Loading...
PhD Nace Zidar

PhD Nace Zidar
no.: 28905 source: ARIS

researcher – active in research organisation
Foreign language skills
Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   

Code Science Field
B740  Biomedical sciences  Pharmacological sciences, pharmacognosy, pharmacy, toxicology 
B230  Biomedical sciences  Microbiology, bacteriology, virology, mycology 
Keywords
medicinal chemistry, drug design, drug synthesis, antibacterial compounds, anticancer compounds, topoisomerases, voltage-gated ion channels
Points
593.23
A''
64.18
A'
375.66
A1/2
480.93
CI10
1,517
CImax
261
h10
22
A1
2.19
A3
0.12
Data for the last 5 years (citations for the last 10 years) on October 15, 2025; Data for score A3 calculation refer to period 2020-2024 (2019)
Data for ARIS tenders ( 23.05.2022 – Target research programmes, archive )
Database Linked records Citations Pure citations Average pure citations
WoS 82  1,903  1,477  18.01 
Scopus 82  2,074  1,634  19.93 
Mentoring junior researchers
source: ARIS
no. Name and surname Type Period Code
1 Martina Piga   Bologna doctoral studies    55894 
Education
source: ARIS
Level of education Professional title Study subject Faculty Year
Bachelor's degree  B. Sc.     SI 2006 
Doctoral degree  Ph. D.   Pharmacy  SI University of Ljubljana, Faculty of Pharmacy 2011 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Employments
source: ARIS
Type of employment Research org. Research group Date of employment Position Role Title
Full time employment (120%, RD:100%)  University of Ljubljana, Faculty of Pharmacy  Chair for Pharmaceutical Chemistry  2/1/2007  Assistant  Researcher  Full professor 
Research projects Legend
source: ARIS
no. Code Title Period Head No. of publications
1. BI-US/24-26-069  Structure-based discovery of new small molecule Hv1 proton channel inhibitors   7/1/2024 - 6/30/2026  PhD Nace Zidar   260 
2. BI-JP/24-26-003  Structure-based discovery of novel Hv1 proton channel inhibitors   4/1/2024 - 4/1/2026  PhD Nace Zidar   260 
3. J1-3031  Development of new inhibitors of bacterial topoisomerases to overcome antimicrobial resistance   10/1/2021 - 9/30/2025  PhD Nace Zidar   1,158 
4. J1-3021  A synthetic biofilm-based platform for studying and development of new antibiofilm strategies   10/1/2021 - 9/30/2024  PhD Iztok Dogša   1,536 
5. N1-0172  Fotokemijski pristop za odkrivanje naprednih ATP-kompetitivnih prob z zaviralnim delovanjem na Topoizomerazo IIalfa (Slovene)   1/1/2021 - 12/31/2023  PhD Janez Ilaš   829 
6. N1-0098  Discovery and mechanism of action of novel hEag1 potassium channel lead molecules with anti-cancer activity   1/1/2019 - 12/31/2022  PhD Lucija Peterlin Mašič   979 
7. J1-9192  New anticancer leads for emerging cancer target potassium ion channels hEag1 and its validation in lymphoma tumors   7/1/2018 - 6/30/2021  PhD Lucija Peterlin Mašič   2,420 
8. Z1-5458  Design, synthesis, and evaluation of new voltage-gated sodium channels modulators   8/1/2013 - 7/31/2015  PhD Nace Zidar   260 
9. J4-4123  Inhibitorji cisteinskih karboksipeptidaz kot regulatorji avtoimunskih in nevrodegenerativnih procesov (Slovene)   7/1/2011 - 6/30/2014  PhD Janko Kos   6,858 
10. L1-4039  Predklinični razvoj novih protimikrobnih učinkovin (Slovene)   7/1/2011 - 6/30/2014  PhD Stanislav Gobec   4,469 
ARIS research and infrastructure programmes Legend
source: ARIS
no. Code Title Period Head No. of publications
1. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2022 - 12/31/2027 PhD Stanislav Gobec   5,846 
2. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2015 - 12/31/2021 PhD Stanislav Gobec   6,517 
3. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2009 - 12/31/2014 PhD Danijel Kikelj   6,386 
4. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2004 - 12/31/2008 PhD Danijel Kikelj   6,446 
International projects
Biography
Nace Zidar graduated from the Faculty of Pharmacy at the University of Ljubljana in 2006 and then joined the Department of Pharmaceutical Chemistry as a young researcher. In 2011, he completed his PhD thesis entitled "Design and Synthesis of Heterocyclic Inhibitors of MurC-E Ligases” under the supervision of Prof. Dr. Danijel Kikelj, for which he received the Krka Prize. In 2017, he completed his postdoctoral training at the Department of Chemistry of the University of Milan. His research focuses on the design, synthesis and evaluation of novel bioactive compounds targeting in particular antimicrobial resistance (bacterial topoisomerases and Mur ligases) and cancer (human topoisomerases and voltage-gated ion channels). He is also interested in the physicochemical characterization of compounds and the development of analytical methods important for pharmaceutical research. He has led a research project on bacterial topoisomerase inhibitors (2021–2024) and a postdoctoral project on voltage-gated sodium channel modulators (2013–2015), both funded by the Slovenian Research Agency. He has been involved in several EU-funded initiatives, such as the IMI ENABLE project (2019–2020) addressing Gram-negative antibiotic resistance, the MSC ITN INTEGRATE network (2015–2019) focusing on the validation of antibacterial targets, and the FP7 MAREX project (2011–2014) exploring marine-derived bioactive compounds. In addition, he has led bilateral collaborations with the United States and Japan and has been an active member of the management committee for several COST Actions.
Views history
Favourite